US2008182329A1PendingUtilityA1

Methods and products related to metabolic interactions in disease

Assignee: UNIV VERMONTPriority: Apr 17, 1998Filed: Aug 17, 2007Published: Jul 31, 2008
Est. expiryApr 17, 2018(expired)· nominal 20-yr term from priority
A61K 2039/57A61K 35/12C07K 14/47G01N 33/56977C07K 14/70532A61K 38/217G01N 33/5005A61K 38/1825A61P 35/00C07K 14/70539A61K 2039/505
73
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention involves methods of regulating cell growth and division to control disease processes by manipulating mitochondrial metabolism and the expression of cell surface immune proteins. The invention also involves related compositions and screening assays.

Claims

exact text as granted — not AI-modified
1 . A method for inducing apoptosis in a tumor cell, comprising:
 contacting a tumor cell with an amount of a metabolic modifying agent, which when exposed to a cell causes coupling of electron transport and oxidative phosphorylation, effective to increase the mitochondrial membrane potential in the tumor cell, wherein the metabolic modifying agent is selected from the group consisting of glucose, an MHC class II HLA-DP/DQ ligand, phorbol myristate acetate in combination with ionomycin, GDP, sodium acetate, UCP antisense, dominant negative UCP, and staurosporine, and   contacting the tumor cell with an amount of an apoptotic chemotherapeutic agent effective for inducing apoptosis in the tumor cell.   
     
     
         2 . The method of  claim 1 , wherein the apoptotic chemotherapeutic agent is selected from the group consisting of adriamycin, cytarabine, doxorubicin, and methotrexate. 
     
     
         3 . The method of  claim 1 , wherein the metabolic modifying agent and the apoptotic chemotherapeutic agent are administered simultaneously. 
     
     
         4 . The method of  claim 1 , wherein the metabolic modifying agent and the apoptotic chemotherapeutic agent are administered locally. 
     
     
         5 . The method of  claim 1 , wherein the tumor cell is resistant to the apoptotic chemotherapeutic agent. 
     
     
         6 . The method of  claim 1 , wherein the tumor cell is sensitive to the apoptotic chemotherapeutic agent, and wherein the amount of metabolic modifying agent is effective to increase mitochondrial membrane potential and the amount of apoptotic chemotherapeutic agent is effective to inhibit the proliferation of the tumor cell when the mitochondrial membrane potential is increased. 
     
     
         7 . A method for inducing apoptosis in a tumor cell, comprising:
 contacting a tumor cell with an amount of a metabolic modifying agent, which when exposed to a cell causes coupling of electron transport and oxidative phosphorylation, effective to increase the mitochondrial membrane potential in the tumor cell, and   contacting the tumor cell with an amount of an apoptotic chemotherapeutic agent effective for inducing apoptosis in the tumor cell, wherein the apoptotic chemotherapeutic agent is selected from the group consisting of cytarabine, doxorubicin, and methotrexate.   
     
     
         8 . The method of  claim 7 , wherein the metabolic modifying agent is selected from the group consisting of glucose, an MHC class II HLA-DP/DQ ligand, phorbol myristate acetate in combination with ionomycin, GDP, sodium acetate, UCP antisense, dominant negative UCP, and staurosporine. 
     
     
         9 . The method of  claim 7 , wherein the metabolic modifying agent and the apoptotic chemotherapeutic agent are administered simultaneously. 
     
     
         10 . The method of  claim 7 , wherein the metabolic modifying agent and the apoptotic chemotherapeutic agent are administered locally. 
     
     
         11 . The method of  claim 7 , wherein the tumor cell is resistant to the apoptotic chemotherapeutic agent.

Join the waitlist — get patent alerts

Track US2008182329A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.